Status:
COMPLETED
PIRLONG-PD Safety and Efficacy of Piribedil in Parkinson's Disease During Long Term Therapy
Lead Sponsor:
Desitin Arzneimittel GmbH
Conditions:
Parkinson's Disease
Eligibility:
All Genders
18+ years
Brief Summary
Non-Ergot Dopamine agonists are meanwhile the drugs of first-choice in the treatment of Parkinson's disease. The receptor profile of the non-ergot dopamine-agonist piribedil is unique. In addition to ...
Eligibility Criteria
Inclusion
- newly diagnosed or advanced idiopathic Parkinson's disease
- male and female patients over 18 years of age
- indication for treatment with piribedil according to Summary of Product Characteristics (SmPC)
Exclusion
- in line with piribedil SmPC
- in particular hypersensitivity to piribedil or to any of the excipients and pregnancy and lactation as stated in the SmPC
Key Trial Info
Start Date :
June 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2015
Estimated Enrollment :
908 Patients enrolled
Trial Details
Trial ID
NCT01519856
Start Date
June 1 2009
End Date
February 1 2015
Last Update
January 29 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr. Erich Scholz
Böblingen, Baden-Wurttemberg, Germany, 71034